T1	Participants 90 178	patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
T2	Participants 180 296	Patient preference for benign prostatic hyperplasia (BPH) treatment with the Î±(1)-blockers, tamsulosin or silodosin
T3	Participants 342 343	.
T4	Participants 344 415	Japanese patients with lower urinary tract symptoms associated with BPH
T5	Participants 825 919	102 patients (mean age 70.3 years) were enrolled and 84 (n = 42 per group) completed the study
T6	Participants 1399 1412	that patients
